Information  X 
Enter a valid email address

Adler Real Estate AG (IRSH)

  Print      Mail a friend

Friday 17 January, 2020

Adler Real Estate AG

Adler Real Estate AG - Consent Results

RNS Number : 1649A
Adler Real Estate AG
17 January 2020
 

THIS ANNOUNCEMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.

 

ADLER Real Estate Aktiengesellschaft announces the effectiveness of the proposed waiver and amendment in connection with the consent solicitation for its outstanding

·    €500,000,000 1.500% notes due 2021 (ISIN: XS1731858392) (the "2021 Notes")

and

·    €300,000,000 2.125% notes due 2024 (ISIN: XS1731858715) (the "2024 Notes"

and, together with the 2021 Notes, the "New York Law Notes").

 

Berlin, January 16, 2020

 

ADLER Real Estate Aktiengesellschaft (the "Issuer") announces that it has received the requisite consents from the holders of a majority of the New York Law Notes as of 5:00 p.m. CET on January 16, 2020 (the "Expiration Time"), pursuant to the Issuer's previously announced consent solicitation, as described in the consent solicitation statement for the New York Law Notes, dated January 8, 2020 (the "Consent Solicitation Statement").

 

As a result of receiving the requisite consents, the Issuer has executed a supplemental indenture to the indenture governing the New York Law Notes and the proposed waiver and amendment have become effective. In accordance with the terms and conditions of the Consent Solicitation Statement, the Issuer will pay the Consent Fee (as defined in the Consent Solicitation Statement) for each noteholder who validly delivered a consent prior to the Expiration Time.

 

Holders  of  the  Issuer's  €400,000,000  1.500%  notes  due  2022  (ISIN:  XS1843441491),

€500,000,000 1.875% notes due 2023 (ISIN: XS1713464441) and €300,000,000 3.000% notes

due 2026 (ISIN: XS1713464524) (together, the "German Law Notes") are advised to refer to the Issuer's announcement dated January 8, 2020, and the consent solicitation statement for the German Law Notes dated January 8, 2020, for information on the ongoing consent solicitation for the German Law Notes. The consent solicitation statement for the German Law Notes is available from the Tabulation Agent and on the Issuer's website at https://adler- ag.com/en/investor-relations/corporate-bonds/       or         https://adler-ag.com/investor- relations/anleihen/.

 

The Issuer has engaged J.P. Morgan Securities plc to act as Solicitation Agent for the consent solicitations. Questions regarding the terms of the consent solicitations may be directed to the Solicitation Agent as follows:

 

Telephone: +44 20 7134 2468

Email: [email protected] Attention: Liability Management

 

The Issuer has also engaged Lucid Issuer Services Limited to act as the Tabulation Agent for the consent solicitations. Questions or requests for assistance or copies of the consent solicitation statements may be directed to the Tabulation Agent as follows:

 

Telephone: +44 207 704 0880 Email: [email protected]


Attention: Paul Kamminga

 

DISCLAIMER

 

This press release is not a consent solicitation and must be read in conjunction with the applicable consent solicitation statement. This press release includes forward-looking statements within the meaning of the securities laws of certain applicable jurisdictions. By their nature, the forward-looking events described in this press release may not be accurate or occur at all. Accordingly, you should not place undue reliance on these forward-looking statements, which speak only as of the date on which the statements were made.

 

 

 

 

 

 

 

 

This announcement has been issued through the Companies Announcement Service of Euronext Dublin.

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ISEGPUUCGUPUUBM

a d v e r t i s e m e n t